Foghorn Therapeutics is expected to report Q3 2026 revenue of approximately $6.39 million and a consensus EPS of -$0.23, while the stock's current price of $2.13 sits well below the analyst price target of $4.17. Investors are primarily focused on the company's strategic pivot and cash runway following the recent discontinuation of its lead FHD-909 program and the termination of its collaboration with Eli Lilly.
To mitigate the loss of its lead clinical asset, Foghorn recently implemented a 40% workforce reduction to extend its operational runway into the second half of 2029. Market participants are now closely monitoring the clinical progress of FHD-286 and the advancement of the company's earlier-stage preclinical oncology pipeline.